In the 1950s, as Japan advanced legal reforms to achieve universal health coverage, the Taisho Pharmaceutical Group began developing medications for dermatological conditions in response to the growing demand for prescription drugs. In 1957, we launched "Solion," a psoriasis treatment, marking our entry into the pharmaceutical business. Since then, we have focused on developing our own innovative medications.

In recent years, we have strengthened our collaboration with external research institutions in drug discovery research, utilizing advanced technologies to continuously create groundbreaking original medications.

The environment surrounding prescription medications has become increasingly challenging due to intensified development competition, healthcare cost containment, and drug price revisions in Japan. In this context, the Taisho Pharmaceutical Group is committed to the continuous creation of new drugs to sustain growth.

We are expanding our drug discovery research to include medium and large molecules, aiming to address unmet medical needs. We are also diversifying our modalities and collaborating with external research institutions to introduce new technologies and engage in joint development. Our goal is to obtain early approval for our development products and expand our pipeline.

Additionally, after product launch, we provide information to healthcare professionals and engage in disease awareness and treatment support activities for patients.

1. Unmet medical needs: Medial needs related to the treatment and cure of diseases for which no effective means of treatment is yet available
2. Modality: Classification of pharmaceuticals based on criteria such as the fundamental technologies used in drug discovery. This includes low-molecular drugs, antibody drugs, nucleic acids therapeutics, cell therapy, gene and cell therapy, gene therapy and other classifications.